119-HR-7895 Investigative Journalist Impact Analysis

Document 119-HR-7895: What it does and where it stands

Scope: prohibits any compensation paid by a PBM (as a covered service provider) to brokers, consultants, advisors, or similar intermediaries for referring employer plan or issuer business; effective for plan years after enactment. [1]GovInfo — H.R. 7895 (IH) — PBM Kickback Prohibition Act (official text)

Status as of May 23, 2026: reported from the House Education & the Workforce Committee following the May 21, 2026 markup; the committee’s own notice and contemporaneous coverage confirm action to advance H.R. 7895. [4]House Committee on Education & the Workforce — Full Committee Markup (May 21, 2…

Regulatory backdrop: the CAA‑2021 already requires brokers/consultants to disclose expected direct and indirect compensation to plan fiduciaries under ERISA §408(b)(2)(B); DOL’s Field Assistance Bulletin 2021‑03 outlines compliance expectations. [2]U.S. Department of Labor (EBSA) — Field Assistance Bulletin No. 2021‑03 — Group…

Economic Effects

Net direction: likely modest reduction in conflict‑driven PBM selection distortions; savings depend on (1) intensity of current PBM‑to‑broker payments, (2) employer uptake of fee‑only consulting, and (3) ability to close affiliate work‑arounds. Evidence highlights below.

• Employer plans: Removing PBM referral payments to brokers/consultants can reduce biased RFPs and vendor lock‑in, improving price and service competition for PBM contracts. Investigative reporting documents per‑script or rebate‑linked payments from PBMs to consulting firms that advise employers. [5]STAT News — Opaque conflicts of interest permeate prescription drug benefits
• Plan fiduciary oversight: The rule aligns with ERISA’s focus on reasonable, conflict‑managed service‑provider compensation; CAA‑2021 already forces disclosure, and a payment ban could further lower conflict risk and litigation exposure over excessive fees. [2]U.S. Department of Labor (EBSA) — Field Assistance Bulletin No. 2021‑03 — Group…
• PBM revenues/cost pass‑through: Reduced marketing/referral outlays could put slight downward pressure on PBM administrative pricing; however, overall drug spending effects are uncertain given other PBM revenue channels. FTC’s interim inquiry highlights how PBM business models and integration can affect prices and pharmacy payments. [3]ftc.gov
• Brokers/consultants: Revenue likely shifts from PBM‑paid commissions to employer‑paid fees or retainers, increasing transparency but raising visible advisory costs for some small and mid‑sized employers. [2]U.S. Department of Labor (EBSA) — Field Assistance Bulletin No. 2021‑03 — Group…
• Spillovers via opacity: While H.R. 7895 doesn’t address spread pricing or rebate retention directly, federal watchdogs have found those opaque practices can inflate payer costs—suggesting complementary transparency/enforcement could amplify savings. [6]HHS Office of Inspector General — Medicaid Managed Care: States Do Not Consiste…

Social Effects

Distributional consequences depend on how employers restructure consulting arrangements and renegotiate PBM contracts.

• Enrollees in employer coverage: If conflict‑free procurement yields lower PBM fees or better pass‑through terms, premiums and out‑of‑pocket costs could ease marginally; the direction is plausible, but the size is indeterminate without accompanying transparency on rebates and spreads. Evidence from the FTC’s inquiry and reporting on consultant payments supports concern about conflict‑driven costs. [3]ftc.gov
• Small employers: Loss of PBM‑funded broker revenue may translate into higher up‑front advisory fees; some may reduce consulting scope, potentially weakening plan purchasing expertise unless offset by consortium buying or fee‑only coalitions. [2]U.S. Department of Labor (EBSA) — Field Assistance Bulletin No. 2021‑03 — Group…
• Pharmacies and community access: By itself, the bill doesn’t regulate pharmacy reimbursement. Still, to the extent cleaner PBM procurement improves terms that reduce cross‑subsidization or volatility, independent pharmacies might see indirect relief; FTC cautions current PBM practices can squeeze pharmacies. Magnitude uncertain. [3]ftc.gov

Environmental Effects

Direct environmental impacts are negligible: the bill targets financial relationships in PBM procurement rather than production, distribution, or utilization patterns with material emissions profiles. Any indirect effects (for example, changes in mail‑order vs. retail dispensing or marketing activity) are speculative and not evidenced in current literature.

Temporal Analysis

• Immediate (enactment to first plan year): PBMs and intermediaries must revise contracts to remove referral compensation; employers will need to validate their brokers’ compensation structures and update fiduciary files accordingly. [1]GovInfo — H.R. 7895 (IH) — PBM Kickback Prohibition Act (official text)
• 1–3 years: Expect migration toward fee‑only consulting and more standardized PBM RFPs; any cost effects should surface at renewal cycles as contracts reprice absent referral fees. Evidence of prior conflicts (e.g., per‑script consultant payments) suggests scope for incremental savings, though results will vary by market concentration. [5]STAT News — Opaque conflicts of interest permeate prescription drug benefits
• Longer‑term: If paired with robust disclosure and audit rights on rebates/spreads, competition for PBM services could strengthen, improving alignment between plan sponsors and enrollees. Without complementary oversight, PBMs may substitute other fees or affiliate pathways, diluting impact. [7]U.S. Government Accountability Office — Selected States’ Regulation of Pharmacy…

Unintended Consequences and Risks

Key risk vectors that could blunt intended effects or create secondary costs.

• Misinterpretation with federal Anti‑Kickback Statute (AKS): H.R. 7895 amends ERISA; it does not change AKS, which governs federal program referrals. Clear guidance will be needed so stakeholders don’t conflate regimes. [9]Frier Levitt — PBM Kickback Prohibition Act: ERISA Reform and Risks for Plan Sp…
• Cost shifting to employers: Eliminating PBM‑funded commissions may raise visible advisory fees for smaller employers that relied on commission models; some could under‑invest in expert procurement, weakening their bargaining position. [2]U.S. Department of Labor (EBSA) — Field Assistance Bulletin No. 2021‑03 — Group…
• Partial impact given market structure: The FTC’s findings on vertical integration and pricing leverage indicate that curbing broker commissions alone won’t address the most powerful incentives affecting formularies and pharmacy payments. [3]ftc.gov

Assessment

Overall stance: neutral. On balance, the bill is analytically favorable for conflict‑reduction and fiduciary clarity in employer PBM contracting, but expected savings are modest and contingent on enforcement that forecloses affiliate work‑arounds and on complementary transparency over rebates/spread pricing. [2]U.S. Department of Labor (EBSA) — Field Assistance Bulletin No. 2021‑03 — Group…

Sourcing and Evidence Base

Most‑relevant sources underpinning this impact map.

• Bill text and effective‑date clause: GovInfo official publication for H.R. 7895. [1]GovInfo — H.R. 7895 (IH) — PBM Kickback Prohibition Act (official text)
• Legislative status: House Education & the Workforce markup notice and post‑markup reporting. [4]House Committee on Education & the Workforce — Full Committee Markup (May 21, 2…
• Existing disclosure framework: DOL Field Assistance Bulletin 2021‑03 on ERISA §408(b)(2)(B) for health‑plan brokers/consultants. [2]U.S. Department of Labor (EBSA) — Field Assistance Bulletin No. 2021‑03 — Group…
• Market conduct and price/policy context: FTC interim staff report on PBMs. [3]ftc.gov
• Documented consultant‑payment conflicts (per‑script/rebate sharing): STAT investigative reporting. [5]STAT News — Opaque conflicts of interest permeate prescription drug benefits
• Opaque pricing risks relevant to complementary reforms: HHS OIG and GAO work on spread pricing/transparency; KFF’s Ohio benchmark. [6]HHS Office of Inspector General — Medicaid Managed Care: States Do Not Consiste…
• State reform landscape for context: MultiState PBM‑reform tracking. [10]MultiState — State PBM Reform: How States Are Trying to Control Pharmaceutical…
• Legal nuance: ERISA vs. AKS distinctions and potential routing through affiliates. [9]Frier Levitt — PBM Kickback Prohibition Act: ERISA Reform and Risks for Plan Sp…